Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis

Roberto Bellucci, Sabine Oertelt, Meagan Gallagher, Sigui Li, Emmanuel Zorn, Edie Weller, Fabrice Porcheray, Edwin P. Alyea, Robert J. Soiffer, Nikhil C. Munshi, M. Eric Gershwin, Jerome Ritz

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

A unique characteristic of the autoimmune liver disease primary biliary cirrhosis (PBC) is the presence of high-titer and extremely specific autoantibodies to the E2 component of the pyruvate dehydrogenase complex (PDC-E2). Autoantibodies to PDC-E2 antigen have only been detected in patients with disease or in those who subsequently develop PBC. One exception has been a subgroup of patients with multiple myeloma (MM) who underwent allogeneic hematopoietic stem cell transplantation (HSCT) and received donor lymphocyte infusions (DLIs) after transplantation. These patients developed high-titer antibodies to a variety of myeloma-associated antigens, including PDC-E2, coincident with rejection of myeloma cells in vivo. To examine the specificity of autoantibodies to PDC in these patients, we screened sera from patients with MM, chronic leukemias, monoclonal gammopathy of unknown significance (MGUS), PBC, and healthy donors. Three of 11 patients with MM (27%) and 2 of 6 patients with chronic leukemias (33%) developed anti-PDC-E2 antibodies in association with DLI response; 2 of 12 (17%) patients in the MGUS pretreatment control population also had detectable anti-PDC responses. Interestingly, the epitope specificity of these PDC-E2 autoantibodies was distinctive, suggesting that the mechanisms leading to loss of tolerance in the transplantation patients are distinct from PBC.

Original languageEnglish (US)
Pages (from-to)2001-2007
Number of pages7
JournalBlood
Volume109
Issue number5
DOIs
StatePublished - Mar 1 2007

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis'. Together they form a unique fingerprint.

  • Cite this

    Bellucci, R., Oertelt, S., Gallagher, M., Li, S., Zorn, E., Weller, E., Porcheray, F., Alyea, E. P., Soiffer, R. J., Munshi, N. C., Gershwin, M. E., & Ritz, J. (2007). Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis. Blood, 109(5), 2001-2007. https://doi.org/10.1182/blood-2006-06-030304